The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
T-Mobile total number of complaints 2012-2015
T-Mobile complaint number
T-mobile Early Termination Fee 2 of 2
T-mobile Early Termination Fee 1 of 2
Metro PCS total number of complaints 2012-2015
First Response to Requester
Request Description
20150513: Impac Mortgage Holdings, Inc.; J. Paul Reddam
1501005 Informal Interpretation
20150420: Thermo Fisher Scientific Inc.; Advanced Scientifics, Inc.
1501003 Informal Interpretation
FTC Staff Comment Before the Federal Communications Commission On Public Notice DA 14-1700, Regarding the Issues Relating To Carrier Implementation of Call-Blocking Technology
Medtronic, Inc. and Covidien plc, In the Matter of
Global medical technology company Medtronic, Inc. agreed to divest the drug-coated balloon catheter business of Ireland-based medical products company Covidien plc, in order to settle FTC charges that its $42.9 billion acquisition of Covidien would likely be anticompetitive. Under the FTC’s proposed settlement, Medtronic will sell the drug-coated balloon catheter business to a Colorado-based medical device company, The Spectranetics Corporation. According to the FTC’s complaint, both Medtronic and Covidien are developing drug-coated balloon catheters to compete with C.R. Bard, Inc., which currently is the only company that supplies these products, used to treat peripheral artery disease, in the U.S. market. Medtronic and Covidien are the only companies with products in clinical trials in the Food and Drug Administration’s approval process, which makes it unlikely that other competitors could enter the market in time to counteract the effects of the merger.